Return to homepagePandemic Pact

Impact of COVID-19 on chronically immunosuppressed neurological patients

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: C19-IUC-035

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    UK Research and Innovation (UKRI)

  • Principal Investigator

    Prof. Paul Matthews

  • Research Location

    United Kingdom

  • Lead Research Institution

    UK Dementia Research Institute

  • Research Priority Alignment

    N/A

  • Research Category

    Epidemiological studies

  • Research Subcategory

    Disease susceptibility

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Individuals with multimorbidityOther

  • Occupations of Interest

    Unspecified

Abstract

Impact of COVID-19 on chronically immunosuppressed neurological patients as an extension of an ongoing pharmacovigilance study of people with multiple sclerosis eligible for treatment. We will assess the impact of chronic immunosuppressive disease modifying treatments (DMT) for multiple sclerosis (OPTIMISE) with an extended focus on collection of COVID-19 related morbidity data collection. The aim is to assess the differential risk of infection with DMT and estimate the relative risks with alternative DMT.